Our primary strategy with VT-122 is aimed at patients with non-resectable pancreatic cancer. This type of pancreatic cancer represents approximately 80% of the pancreatic cancer cases in the US, EU and Japan. We are initially focused on the treatment of patients with non-resectable metastatic pancreatic cancer receiving nab-paclitaxel plus gemcitabine.
Despite advances in the treatment of these patients, most will progress on nab-paclitaxel plus gemcitabine with an expected survival of less than one year. We believe that our strategy to damp tumor-promoting inflammation, restore immune surveillance and improve treatment tolerance with VT-122 may significantly improve outcomes for pancreatic cancer patients.